First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor - Takeaways - MDSpire

First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor

  • By

  • Juan Bu

  • Yeledan Mahan

  • Reziwanguli Yuemaier

  • Xiaoling Zhang

  • Ling Zhou

  • May 20, 2026

  • 0 min

Share

  • 1

    Imatinib is a tyrosine kinase inhibitor used for treating gastrointestinal stromal tumors (GIST) and chronic myeloid leukemia.

  • 2

    This case presents a novel instance of hypouricemia associated with adjuvant imatinib therapy in a patient with intestinal GIST.

  • 3

    Common adverse events of imatinib include peripheral edema, nausea, vomiting, and hematologic abnormalities like decreased blood cell counts.

  • 4

    The patient experienced a progressive decline in serum uric acid levels during imatinib treatment, reaching a low of 96 μmol/L.

  • 5

    Post-treatment, the patient's serum uric acid levels normalized, indicating a potential link between imatinib and hypouricemia.

Original Source(s)

First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor

  • by Juan Bu, Yeledan Mahan, Reziwanguli Yuemaier, Xiaoling Zhang, Ling Zhou

  • May 20, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

High-grade astrocytoma with piloid features: a case report of comprehensive management